News
GMP Grade Trivehexin® now available!
Ga-68-Trivehexin invented at TU Munich.
Who we are, where we are.
TRIMT is an inventor-founded, science and data driven company, managed and operated by experts with a strong scientific background who are supported by an interdisciplinary board of advisors. We value a creative, out-of-the-box thinking and communication approach leading to disruptive innovation.
TRIMT GmbH founded in Radeberg (Saxony) in 2021, taking advantage of a thriving local community of research institutes, radiopharmaceutical industry, and clinical partners, and funding opportunities.
Management
PD Dr. Johannes Notni
Managing Partner
Dr. Dirk Freitag-Stechl, MBA
Managing Partner
What we do, and why.
TRIMT‘s Pipeline is widely orthogonal to mainstream research, granting leadership in our market sector.
The global market for radio-theranostics is expected to grow substantially.
TRIMT is committed to driving innovation and advancement in theranostics with a combination of unique technologies.
Our Advisory Board.
An interdisciplinary team, covering all expertise needed in translational Theranostics development.
Prof. Dr. Constantin Lapa
Nuclear Medicine
University Hospital Augsburg (DE)
Prof. Dr. Margret Schottelius
Translation & Immunology
CHUV
Lausanne (CH)
Priv.-Doz. Dr. Katja Steiger
Preclinics & Translation
Technical University of Munich (DE)
Prof. Dr. Marianne Patt
Radiopharmaceuticals Regulatory & GMP
Technical University of Munich (DE)
Dr. Wolfgang Burger
Business Development
CEO of LyoMark
Oberhaching (DE)